Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, identifying high growth tech stocks that align with these promising trends can be a valuable addition to a diversified portfolio.
Top 10 High Growth Tech Companies In The United States
| Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
| Marker Therapeutics |
61.33% |
65.71% |
★★★★★★ |
| Palantir Technologies |
27.35% |
30.93% |
★★★★★★ |
| |
22.05% |
27.75% |
★★★★★★ |
| Fabrinet |
20.36% |
22.11% |
★★★★★★ |
| Gorilla Technology Group |
54.35% |
95.02% |
★★★★★☆ |
| Sandisk |
34.05% |
49.66% |
★★★★★★ |
| Zscaler |
15.95% |
49.84% |
★★★★★☆ |
| Procore Technologies |
12.08% |
101.03% |
★★★★★☆ |
| Duos Technologies Group |
36.60% |
141.19% |
★★★★★☆ |
| KVH Industries |
25.44% |
135.75% |
★★★★★☆ |
Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Daktronics
Simply Wall St Growth Rating:★★★★☆☆
Overview:Daktronics, Inc. is a company that specializes in designing, manufacturing, and selling electronic scoreboards and display systems for various applications globally, with a market capitalization of approximately $930.70 million.
Operations:The company generates revenue primarily from five segments: Commercial ($181.01 million), Live Events ($295.79 million), International ($76.98 million), Transportation ($71.43 million), and High School Park and Recreation ($177.44 million).
Daktronics has demonstrated an impressive ability to innovate and capture high-profile projects, as evidenced by their recent installation of advanced LED displays at Yankee Stadium and Los Angeles International Airport. These installations, which feature millions of pixels for enhanced visual experience, underscore the company's commitment to leading-edge technology in digital signage. Financially, Daktronics has shown robust performance with a 2561.6% earnings growth over the past year significantly outpacing the industry average of 15.7%. However, its revenue growth forecast at 8.3% annually trails behind the US market projection of 10.9%. This juxtaposition highlights a strong profit generation capability tempered by slower relative revenue expansion in a competitive market environment.
-
Click here and access our complete health analysis report to understand the dynamics of Daktronics.
-
Gain insights into Daktronics' historical performance by reviewing our past performance report.
Neurocrine Biosciences
Simply Wall St Growth Rating:★★★★★☆
Overview:Neurocrine Biosciences, Inc. is a company that focuses on discovering, developing, and commercializing pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders both in the United States and internationally with a market cap of approximately $13.19 billion.
Operations:Neurocrine Biosciences generates revenue primarily from the research, development, commercialization, and sale of pharmaceuticals, amounting to $2.86 billion.
Neurocrine Biosciences has demonstrated significant strides in addressing congenital adrenal hyperplasia (CAH) with its innovative drug, CRENESSITY, which offers a non-glucocorticoid approach to managing the condition. Recent Phase 3 study results showcased at the American Association of Clinical Endocrinology Annual Meeting reveal sustained reductions in glucocorticoid doses, marking a pivotal advancement in treatment protocols. Financially, the company's robust R&D investment aligns with its strategic focus on novel therapies, supporting a promising revenue trajectory forecasted to grow at 12.5% annually. Moreover, Neurocrine's earnings are expected to surge by 26.4% per year over the next three years, outpacing broader market projections and underscoring its potential within biotech innovation.
-
Dive into the specifics of Neurocrine Biosciences here with our thorough health report.
-
Assess Neurocrine Biosciences' past performance with our detailed historical performance reports.
Vishay Precision Group
Simply Wall St Growth Rating:★★★★☆☆
Overview:Vishay Precision Group, Inc. operates in the precision measurement and sensing technologies sector across the United States, Europe, Israel, Asia, and Canada with a market capitalization of $762.07 million.
Operations:The company generates revenue primarily from its Sensors, Weighing Solutions, and Measurement Systems segments, with Sensors contributing $117.17 million and Weighing Solutions adding $111.80 million. The Measurement Systems segment accounts for $80.41 million in revenue.
Vishay Precision Group, despite a challenging year marked by a net loss in Q4 2025, continues to navigate through volatile markets with strategic emphasis on R&D and innovation. Recent presentations at high-profile conferences underscore their commitment to transparency and growth within the electronic components industry. With an expected rebound, earnings are forecasted to grow by an impressive 64.8% annually over the next three years, outstripping broader market projections of 15.9%. This optimistic outlook is further bolstered by a robust projected return on equity of 28.5%, positioning VPG well for future advancements despite current hurdles.
Summing It All Up
-
Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 65 more companies for you to explore.Click here to unveil our expertly curated list of 68 US High Growth Tech and AI Stocks .
-
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
-
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Interested In Other Possibilities?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
-
Find companies with promising cash flow potential yet trading below their fair value .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DAKT NBIX and VPG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
